Catalyst Wire Dossier Catalyst Wire Dossier

Ranluspec

ranibizumab · Lupin Europe GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ranluspec, covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH

See pricing